Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture
You may also be interested in...
Ajinomoto's Earthquake Response At Fukushima: A Business Continuity Case Study
Shinji Oshiguchi, the plant manager for Ajinomoto's Fukushima production plant, outlines the precautionary steps, response, and restarting protocols during a natural disaster.
Takeda Expands Abroad While Finding Its Way In Its Home Market
TOKYO - Takeda Pharmaceutical Co. Ltd. made a number of moves this week to expand its presence in Europe and China, including licensing Dainippon Sumitomo Co. Ltd.'s antipsychotic agent lurasidone in 26 EU member states and committing to more than triple its sales reps in China by 2015. But in Japan, Takeda and other pharma still grapple with assessing how the Tohoku earthquake has changed the Japanese market
Takeda Expands Abroad While Finding Its Way In Its Home Market
TOKYO - Takeda Pharmaceutical Co. Ltd. made a number of moves this week to expand its presence in Europe and China, including licensing Dainippon Sumitomo Co. Ltd.'s antipsychotic agent lurasidone in 26 EU member states and committing to more than triple its sales reps in China by 2015. But in Japan, Takeda and other pharma still grapple with assessing how the Tohoku earthquake has changed the Japanese market